Abstract
Anal carcinoma is an uncommon disorder accounting for less than 2% of large bowel malignancies and 1–6% of anorectal tumours. Its incidence ranges between 0.5 and 1% per 100,000. Local staging should be done with MR imaging using an external pelvic phased-array coil. Treatment strategy should be optimally discussed in a multidisciplinary team. HIV-positive patients seem to achieve similar response rate and overall survival to HIV-negative patients but with increased toxicity and higher local recurrences. Combined modality treatment with irradiation and chemotherapy has resulted in complete response over 90% and local control over 85%. This guide gives recommendations for diagnosis, staging and treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Palfsky JM, Holly EA, Ralston ML et al (1998) High incidence of high grade squamous intraepithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 12:495–503
Glynne-Jones R, Northover JMA, Cervantes A (2010) Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21[Suppl 5]:v87–v92
Koh DM, Dzik-Jurasz A, O’Neill B et al (2008) Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol 81:91–98
Eschwege F, Lasser P, Chavy A et al (1985) Squamous cell carcinoma of the anal canal: treatment by external beam radiation. Radiother Oncol 3:145
Newman G, Calverley DC, Acker BD et al (1992) The management of carcinoma of the anal canal by external beam radiotherapy, experience in Vancouver 1971–1988. Radiother Oncol 25:196
(1996) Epidermoid anal cancer: results from UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054
Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Group. J Clin Oncol 15:2040–2049
Meropol N, Niedzwiecky D, Shank B et al (2005) Combined-modality therapy of poor prognosis anal carcinomas: a phase II study of the Cancer and Leukemia Group B (CALGB). ASCO Cancers Symposium 238
Ajani JA, Winter KA, Gunderson LL et al (2008) Intergroup RTOG 98-11: fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–1921
Oehler-Jänne C, Huguet F, Provencher S et al (2008) HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 26:2550–2557
Hoffman R, Welton ML, Klencke B et al (1999) The significant of pre-treatment CD4 count on the outcome and treatment tolerance of HIV positive patients with anal cancer. Int J Radiat Oncol Biol Phys 44:127–131
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maurel, J., Fernández-Martos, C., Feliu, J. et al. SEOM clinical guidelines for the treatment of anal cancer. Clin Transl Oncol 13, 525–527 (2011). https://doi.org/10.1007/s12094-011-0692-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0692-z